Category: Summaries

People’s Republic of China Drug Administration Law
This document is effective 01 December 2019. SIGNIFICANT – NMPA for the first time – delayed implementation. Significant increases in [...]
Read More
Regulations for the Administration of Overseas Inspection of Pharmaceuticals & Medical Devices
The National Medical Products Administration (NMPA) of China issued the “Provisions on the Administration of Overseas Inspection of Drugs and [...]
Read More
Data Integrity and Compliance With Drug CGMP Questions and Answers Guidance for Industry
The Food and Drug Administration (FDA) created a questions and answers document to clarify the role of data integrity in [...]
Read More
Guideline on the Quality of Water for Pharmaceutical Use
The document is intended to provide guidance to the industry on pharmaceutical use of different grades of water in the [...]
Read More
Health Canada: Notifying Health Canada of Foreign Actions
Health Canada has issued a Q&A guidance document regarding notifications of foreign actions.  The intent is to improve the collection [...]
Read More
Safety Features for Medicinal Products for Human Use Questions and Answers Version 12
This slide deck addresses Safety Features for Medicinal Products for Human Use (version 12) prepared by the European Commission Directorate-General [...]
Read More
EU Annex 17 – Real Time Release and Parametric Release
Annex 17, Real Time Release Testing and Parametric Release, published by the European Commission, outlines the requirements for application of [...]
Read More
EMA/CAT/80183/2014: Guideline on the Quality, Non-Clinical and Clinical Aspects of Gene Therapy Medicinal Products (GTMP)
The EMA guideline on quality, non-clinical and clinical aspects of gene therapy medicinal products (GTMP´s) builds on earlier documentation and [...]
Read More
PIC/S Guidelines on GDP of Active Substances for Medicinal Use
This document provides Pharmaceutical Inspection Convention Cooperation Scheme (PIC/S) Guidelines on the Principles of Good Distribution Practice of Active Substances [...]
Read More
ICH Q12 on Pharmaceutical Product Lifecycle Management was issued for public consultation
ICH Q12 Draft Guideline provides the framework to facilitate the management of post-approval CMC changes in a predictable and efficient [...]
Read More
Standardization of Data and Documentation Practices for Product Tracing Guidance for Industry
On February 28, 2018, FDA issued draft guidance on Standardization of Data and Documentation Practices for Product Tracing. This draft guidance aims [...]
Read More
Pic/s Guidelines On The Principles Of Good Distribution Practice Of Active Substances For Medicinal Products…
These guidance’s are based on current Good Distribution Practices (GDP) for importers and providers of the distribution of active substances [...]
Read More
PIC/S Guidelines on Excipient GMP Risk Assessment
The present PIC/S Guidelines is based on EC document 2015/C 95/02, and has been adopted by PIC/S as a guidance [...]
Read More
Announcement on the Matters related to filing and Joint Review & Approval of Active Pharmaceutical…
The CNDA (formerly CFDA) has issued an announcement which clarifies the expectations for when excipient suppliers, API suppliers and packing [...]
Read More
PIC/S GMP GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART I
PIC/S has developed guides aimed at promoting the harmonization of GMP standards and guidance documents.  The PIC/S GMP Guides have [...]
Read More
Implementation of International Council for Harmonisation (ICH) of Technical Requirements of Pharmaceuticals for Human Use…
The objective of this guideline is to recommend acceptable amounts for residual solvents in pharmaceuticals for the safety of the [...]
Read More
Annex 1 to the Good Manufacturing Practices Guide – Manufacture of Sterile Drugs (GUI-0119) Canada
Health Canada’s Annex 1 to the Good Manufacturing Practices Guide for Manufacture of Sterile Drugs (GUI-0119) will be implemented 01 [...]
Read More
MHRA ‘GXP’ Data Integrity Guidance and Definitions
The MHRA published ‘GXP’ Data Integrity Guidance and Definitions in March 2018. The scope of this guidance is designated as ‘GXP’ [...]
Read More
GMP Guide for Drug Products GUI-001 Canada
This document offers guidelines for interpretation of Good Manufacturing Practices (GMP) as applied in Canada in order to comply with [...]
Read More
EU SAFETY FEATURES FOR MEDICINAL PRODUCTS FOR HUMAN USE QUESTIONS AND ANSWERS – VERSION 9
The European Commission Directorate-General for Health and Food Safety has prepared Question and Answers document to address questions regarding 2019 [...]
Read More
Definitions of Suspect Product & Illegitimate Product for Verification Obligations Under the Drug Supply Chain…
The Drug Supply Chain Security Act ( DSCSA ) amended the Federal Food, Drug, and Cosmetic Act ( FD&C Act [...]
Read More
FDA Unique Device Identification: Direct Marking of Devices
Unique Device Identification:  Direct Marking of Devices is a guidance document issued by the FDA on 17 November 2017 to [...]
Read More
FDA Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier
On November 27, 2017, FDA issued a draft guidance to help trading partners (manufacturers, repackagers, wholesale distributors, and dispensers) understand their compliance [...]
Read More
Annex 1 on Manufacturing of Sterile Medicinal Products, of the Eudralex Volume 4
Annex 1 “Manufacturing Of Sterile Medicinal Products” of the EU GMP Guide was first published in 1971, since then it [...]
Read More
EU SAFETY FEATURES FOR MEDICINAL PRODUCTS FOR HUMAN USE QUESTIONS AND ANSWERS VERSION 8
The European Commission Directorate-General for Health and Food Safety has prepared Question and Answers document to address questions regarding 2019 [...]
Read More
EMA Guideline on Manufacture of the Finished Dosage Form
The purpose of this guidance is to provide clarification on the type and level of information to be included in [...]
Read More
Classification of Products as Drugs and Devices & Additional Product Classification Issues: Guidance for Industry…
FDA is providing final guidance on issues frequently raised in relation to Requests for Designation (RFDs) and other classification activities.  [...]
Read More
EMA Implementation plan for the introduction of the safety features on the packaging of centrally…
New legislative requirements from the European Medicines Agency and the European Commission, specifically the new Commission Delegated Regulation (EU) 2016/161) [...]
Read More
Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy.
The Drug Supply Chain Security Act (DSCSA) was signed into law on November 27, 2013. Section 202 of the DSCSA [...]
Read More
CANADA GAZETTE – Regulations Amending the Food and Drug Regulations (Importation of Drugs for an…
The objective of the regulatory amendments is to enable access to drugs that would help address an urgent public health [...]
Read More
European Commission – Safety Features for Medicinal Products for Human Use – Q&A version 7
The European Commission provided an update to the Questions and Answers regarding “Safety Features For Medicinal Products For Human”.  This [...]
Read More
FDA – Enhanced Drug Distribution Security Under the Drug Supply Chain Security Act (DSCSA)
Enhanced drug distribution security needs September 22, 20172 December 5-6, 2017 9:00am to 4:00pm EST   (Advance Registration: October 2-27, [...]
Read More
Regulation (EU) 2017/746 of the European Parliament & Council of 4/5/17 on in vitro diagnostic…
The European regulations governing in vitro diagnostic devices have recently been updated, and enter into force on 26 May 2022 [...]
Read More
MHRA GMP Inspection Deficiency Data Trend 2016
The MHRA has improved the way of gathering the inspection deficiency data for 2016. The new data trending can allow [...]
Read More
FDA Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification
On December 9, 2016, FDA issued guidance for industry entitled ‘‘Drug Supply Chain Security Act Implementation: Identification of Suspect Product [...]
Read More
EMA Implementation Strategy of ICH Q3D Guideline
On 08 March 2017, EMA issued an implementation strategy of the ICH Q3D guideline that addresses specific considerations to enable [...]
Read More
EU ICH Guideline Q3C R6 on Impurities Guideline for Residual Solvents
On 6 December 2016 the European Medicines Agency issued a revision to the “ICH guideline Q3C (R6) on Impurities: Guideline [...]
Read More
Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products
This guidance describes and explains the final rule on current good manufacturing practice (CGMP) requirements for combination products that FDA [...]
Read More
Agreement on Mutual Recognition Between EU Community and US FDA
The US FDA and the EU announced that they have completed an exchange of letters to amend the Pharmaceutical Annex [...]
Read More